Protalix BioTherapeutics (Israel) Profile

161.20
ILS 7.80  5.08%
100%
44%

Protalix BioTherapeutics Summary

Protalix BioTherapeutics (PLX) is traded on Tel Aviv Stock Exchange in Israel. It is located in 2 Snunit Street and employs 190 people. The company currently falls under 'Small-Cap' category with current market capitalization of 228.51 M. Protalix BioTherapeutics has 129.08 M outstanding shares. PROTALIX BIOTCS has accumulated about 41.32 M in cash with (10.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28.
Check Protalix BioTherapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Key Fundamentals

Protalix BioTherapeutics Against Markets

Current Ratings

Protalix BioTherapeutics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
6 
Chance of
Financial Distress (0 to 100%)
41 
Equity ratings for Protalix BioTherapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel. Protalix BioTherapeutics operates under Biotechnology classification in Israel and traded on Tel Aviv Stock Exchange. It employs 190 people. more
NameProtalix BioTherapeutics
CEO and President and DirectorMoshe ManorView All
Macroaxis Advice
InstrumentIsrael Stock View All
Business Address2 Snunit Street
Foreign Associate  USA
ExchangeTel Aviv Stock Exchange
SectorHealthcare
BenchmarkDOW
Websitewww.protalix.com
Phone972 4 988 9488
CurrencyILS - Israeli Shekel

Did you try this?

Run Portfolio Volatility Now
   

Portfolio Volatility

Check portfolio volatility and analyze historical return density to properly model market risk
All  Next Launch Portfolio Volatility

Protalix BioTherapeutics Corporate Directors

Roger Kornberg Independent Director, Ph.D
Amos BarShalev Independent Director, MBA
Aharon Schwartz Independent Director, Ph.D
Additionally take a look at Your Equity Center. Please also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.